Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors

BMC Infectious Diseases

Research Article

Gary Maartens¹  Helen McIlleron¹  Feriyl Bhaijee²  Graeme Meintjes³  Dominique J Pepper³  Suzaan Marais³  Robert J Wilkinson⁴  Janisha Patel⁵  Virginia De Azevedo⁶  Simiso Sokhela⁶  Helen Cox⁷  Cheryl McDermid⁸ 

[1] Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa;Groote Schuur Hospital, Cape Town, South Africa;Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa;Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa;Department of Medicine, University of Cape Town, South Africa;Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa;Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa;Department of Medicine, University of Cape Town, South Africa;Division of Medicine, Imperial College of London, London, UK;MRC National Institute for Medical Research, Mill Hill, NW7 1AA, London, UK;Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa;Khayelitsha Site B Tuberculosis Clinic, City Health, Cape Town, South Africa;Macfarlane Burnet Institute for Medical Research and Public Health, Australia;MedecinsSans Frontieres, Cape Town, South Africa;

关键词: Tuberculosis;    Tuberculosis Patient;    Clinical Deterioration;    Drug Susceptibility Testing;    Tuberculosis Diagnosis;   

DOI  :  10.1186/1471-2334-10-83

 received in 2009-11-13, accepted in 2010-03-30,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundHIV-1 and Mycobacterium tuberculosis cause substantial morbidity and mortality. Despite the availability of antiretroviral and antituberculosis treatment in Africa, clinical deterioration during antituberculosis treatment remains a frequent reason for hospital admission. We therefore determined the incidence, causes and risk factors for clinical deterioration.MethodsProspective cohort study of 292 adults who initiated antituberculosis treatment during a 3-month period. We evaluated those with clinical deterioration over the following 24 weeks of treatment.ResultsSeventy-one percent (209/292) of patients were HIV-1 infected (median CD4+: 129 cells/μL [IQR:62-277]). At tuberculosis diagnosis, 23% (34/145) of HIV-1 infected patients qualifying for antiretroviral treatment (ART) were receiving ART; 6 months later, 75% (109/145) had received ART. Within 24 weeks of initiating antituberculosis treatment, 40% (117/292) of patients experienced clinical deterioration due to co-morbid illness (n = 70), tuberculosis related illness (n = 47), non AIDS-defining HIV-1 related infection (n = 25) and AIDS-defining illness (n = 21). Using HIV-1 uninfected patients as the referent group, HIV-1 infected patients had an increasing risk of clinical deterioration as CD4+ counts decreased [CD4+>350 cells/μL: RR = 1.4, 95% CI = 0.7-2.9; CD4+:200-350 cells/μL: RR = 2.0, 95% CI = 1.1-3.6; CD4+<200 cells/μL: RR = 3.0, 95% CI = 1.9-4.7]. During follow-up, 26% (30/117) of patients with clinical deterioration required hospital admission and 15% (17/117) died. Fifteen deaths were in HIV-1 infected patients with a CD4+<200 cells/μL.ConclusionsIn multivariate analysis, HIV-1 infection and a low CD4+ count at tuberculosis diagnosis were significant risk factors for clinical deterioration and death. The initiation of ART at a CD4+ count of <350 cells/μL will likely reduce the high burden of clinical deterioration.

【 授权许可】

CC BY   
© Pepper et al; licensee BioMed Central Ltd. 2010